Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 4

INITIALL: Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

NCT ID: NCT06289673Sponsor: St. Jude Children's Research HospitalLast updated: 2026-05-01

Summary

The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies. * To develop a central database of genomic and clinical findings. Secondary Objectives * To assess event free and overall survival data of patients enrolled on this study.

Detailed description

Patients with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL/LLy) and mixed phenotype acute leukemia/lymphoma (MPAL) will undergo diagnostic procedures either during screening or on Day 1. They will receive 7 days of chemotherapy including 13 doses of dexamethasone, 1 dose of vincristine, and 1 dose of daunorubicin (for patients with T-ALL/LLy or MPAL only). Patients will also undergo their initial lumbar puncture with intrathecal chemotherapy on Days 4 or 5 or 6 of therapy. After the completion of 7 days of chemotherapy, patients will begin therapy on either a SJALL therapeutic trial or will receive non-protocol therapy.

Arms & interventions

  • DrugDexamethasone

    Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7

  • DrugVincristine

    Intravenously (IV) for 1 dose on Day 1 or 2

  • DrugDaunorubicin

    Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)

  • DrugIntrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)

    Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6

  • DrugMethotrexate

    Given IT as part of Intrathecal triple therapy.

  • DrugCytarabine

    Given IT as part of Intrathecal triple therapy.

Outcome measures

Primary

  • Sufficient phenotypic and/or genomic data necessary for therapeutic protocol assignment by Day 8 (completion of INITIALL therapy).

    The proportion of patients with sufficient immunophenotypic, genomic, and clinical data to allow determination of eligibility for currently open trials at the enrolling institution.

    Time frame: 1 week from study entry

  • Complete data within the INITIALL database

    The proportion of patients with complete data within the INITIALL protocol database as described in the protocol.

    Time frame: 3 months, 1 year, 3, 5 years from study entry

Secondary

  • Event Free Survival (EFS)

    Time frame: 1, 3, 5 years from study entry

  • Overall Survival (OS)

    Time frame: 1, 3, 5 years from study entry

Eligibility criteria

Sex: AllAge: 1 Year to 18 YearsHealthy volunteers: No
Inclusion Criteria: * Age 1-18.99 years * Diagnosis of acute leukemia / lymphoma as below: * Acute lymphoblastic leukemia (ALL) with at least 25% bone marrow blasts or definitive evidence of ALL in peripheral blood (in those without an available bone marrow sample). * Lymphoblastic lymphoma (LLy) with immunophenotypic evidence of a lymphoblastic population and \<25% bone marrow blasts and less than 1,000 circulating blasts/ microL. * Mixed phenotype acute leukemia (MPAL) with or without 25% bone marrow involvement (i.e. patients with either leukemia or lymphoma are eligible). Exclusion Criteria: * Pregnant or breastfeeding * Receipt of prior cancer directed therapy with the exclusion of up to 1 dose of intrathecal chemotherapy, 1 dose of vincristine, or emergency radiotherapy due to organ compromising malignant mass. There is no exclusion for prior steroid therapy. * Known to be currently ineligible for available SJALL therapeutic studies (e.g. receipt of prohibited therapy, no appropriate SJALL therapeutic study available, enrolled on competing trial, etc.). Note: The intention of this exclusion criterion is to enroll all newly diagnosed ALL/ LLy/ MPAL patients. If participant is screened as a potential participant for subsequent SJALL and later found to be ineligible due to information obtained during INITIALL, this will not make the participant ineligible for INITIALL. * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. * Major pre-existing abnormalities such as ataxia telangiectasia, Fanconi anemia, Charcot Marie Tooth, etc.

Study locations (3)

Rady Children's Hospital

San Diego, California, 92123

Recruiting
Victor Wong, MD · Contact
858-966-5811vwong@rchsd.org
Victor Wong, MD · Principal Investigator

Saint Francis Children's Hospital

Tulsa, Oklahoma, 74136

Recruiting
Ashraf Mohamed, MD · Contact
918-502-6720ammohamed@saintfrancis.com
Ashraf Mohamed, MD · Principal Investigator

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105

Recruiting
Seth E. Karol, MD · Contact
888-226-4343referralinfo@stjude.org
Seth E. Karol, MD · Principal Investigator